2024-516865-35-01招募中4 期
Head-to-Head Comparison of the Efficacy and Safety of All Commercially Available Botulinum Neurotoxin Type A Products for the Treatment of Glabellar Rhytides: A Multicenter, Triple-Blind, Randomized Controlled Trial
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 5
- 主要终点
- The primary outcome measure will be the time until loss of treatment effect. This is specifically quantified as the period until a loss of effect is observed and measured as the percentage of participants who maintain at least a 1-point improvement in glabellar line severity at maximum frown from baseline to week 16, assessed using the "four-point clinical severity score for glabellar frown lines" developed by Honeck.
研究概览
简要总结
Clinical Efficacy (Duration) By directly comparing all six commercially available BoNT-A products this trial seeks to provide definitive evidence to inform clinical decision-making and optimize patient outcomes. The primary objective is to compare these products head-to-head in order to determine superiority in clinical efficacy (duration).
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Inclusion Criteria In order to be eligible to participate in this study, a subject must meet all of the following criteria: • Women aged 18 years or over, with moderate to severe glabellar lines. • Willing to provide written informed consent. • American Society of Anesthesiologists (ASA) Physical Status Classification 1 or 2.
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study: • ASA Classification 3 or over: Patients with a higher ASA score are at increased risk during any medical procedure due to existing severe systemic disease. • History of hypersensitivity or adverse reactions to botulinum toxin or any of its components: To prevent potential allergic reactions or severe side effects. • Infection at the injection site: To avoid exacerbation of infection or interference with the efficacy and safety assessment of the product. • Previous treatment with botulinum toxin (lifetime): To ensure no interference from previous BoNT-A treatments affects study outcomes. • Pregnant or breastfeeding women: To avoid any risk to the developing fetus or newborn. • Peripheral motor neuron diseases (e.g., ALS, Lambert-Eaton syndrome, myopathy) or pre-existing muscle weakness, swallowing or breathing problems: To prevent worsening of symptoms or complications due to underlying neuromuscular instability. • Body Dysmorphic Disorder (assessed with screening tool; Prof. Ad de Jongh; Nederlandse vertaling en bewerking van een screeningslijst t.b.v. cosmetische en chirurgische ingrepen; Cunningham et al.,
- •British Journal of Orthodontics, 25, p.293-298): To exclude individuals who may have unrealistic expectations or psychological issues related to their appearance. • Medications that act on the motor endplate that could potentiate the effect of BoNT-A: This includes aminoglycosides, cholinesterase inhibitors, succinylcholine, curare-like depolarization blockers, magnesium sulfate, quinidine, calcium channel blockers, lincosamides, polymyxins. These drugs could interact with BoNT-A, potentially leading to exaggerated effects or systemic toxicity.
结局指标
主要结局
The primary outcome measure will be the time until loss of treatment effect. This is specifically quantified as the period until a loss of effect is observed and measured as the percentage of participants who maintain at least a 1-point improvement in glabellar line severity at maximum frown from baseline to week 16, assessed using the "four-point clinical severity score for glabellar frown lines" developed by Honeck.
The primary outcome measure will be the time until loss of treatment effect. This is specifically quantified as the period until a loss of effect is observed and measured as the percentage of participants who maintain at least a 1-point improvement in glabellar line severity at maximum frown from baseline to week 16, assessed using the "four-point clinical severity score for glabellar frown lines" developed by Honeck.
次要结局
- Secondary Outcome Related to Clinical Efficacy: (Duration) a. Duration of Treatment Effect (Detailed Analysis): While the primary outcome captures the time until loss of effect at week 16, as secondary outcomes we will employ Kaplan-Meier survival curves and Cox proportional hazards models to analyze the time to complete loss of effect across the entire study duration. This analysis will provide additional insights into the robustness of the treatment's effects, allowing us to identify the media
- Secondary Outcome Related to Safety: a. Incidence of Adverse Events (AEs): Monitors occurrences of adverse events such as ptosis, strabismus, and eyelid sensory disorders throughout the study period.
- Patient-Reported Outcomes (assessed from baseline to week 16): a. Quality of Life (FACE-Q Psychological Wellbeing): Evaluates the impact of treatment on psychological wellbeing. b. Social Functioning (FACE-Q Social):44 Assesses the effect of treatment on social interaction capabilities. c. Participant Self-Assessment of Satisfaction (FACE-Q Satisfaction): Measures patient satisfaction with treatment outcomes.
- Psychological Assessments: a. Hospital Anxiety and Depression Scale (HADS): Assessed from baseline to week 4 to monitor changes in anxiety and depression levels. b. Migraine Disability Assessment (MIDAS) / Headache Impact Test (HIT-6): Assessed from baseline to week 4 to evaluate the impact on headache and migraine symptoms.
- Side Effects (assessed within the first two weeks): a. FACE-Q Early Life Impact: Evaluates immediate post-treatment effects on patients’ daily life.
研究者
Prof. dr. J. de Lange
Scientific
Stichting Amsterdam UMC
研究点 (5)
Loading locations...
相似试验
招募中
2 期
Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand DiseaseNCT07273721Medical University of Vienna6
招募中
1 期
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid TumorsNCT07296341Shanghai Hengrui Pharmaceutical Co., Ltd.60
招募中
1 期
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune DiseasesNCT07275736Juventas Cell Therapy Ltd.18
尚未招募
1 期
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune DiseasesNCT07265206Juventas Cell Therapy Ltd.15
Enrolling By Invitation
不适用
Persona SoluTion PPS Femur PMCFNCT07286513Zimmer Biomet200